Ferring has licensed from Albireo the world rights to elobixibat, excluding those territories held by Ajimoto. Elobixibat is a first-in-class...
The FDA on 30 August 2012 approved Linzess (linaclotide) from Forest Labs and Ironwood Pharma, to treat Chronic Idiopathic Constipation...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...
AstraZeneca has filed a new drug submission with the FDA for Naloxegol (naxolol), for the treatment of Opioid induced Constipation....
Sucampo and Takeda announced topline results from a pharmacodynamic, PK and tolerability Phase III study of a liquid formulation of...
Albireo Limited announced positive top-line results from a pivotal Phase III clinical trial of its product candidate, elobixibat, in chronic...
Knight Therapeutics Inc., has announced that Health Canada has approved Ibsrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
Further analysis of the Phase III KODIAC-04, KODIAC-05 and KODIAC-08 studies showed that Movantik (naloxegol), from AstraZeneca, had a similar...
Moventig (naloxegol) from AstraZeneca was approved in the EU on 8 December 2014 for treatment of opioid-induced constipation in adult...
AstraZeneca has announced that Moventig (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of...